Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer

Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096

de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618

Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095

Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506

Badrising, 2014, Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment, Cancer, 120, 968, 10.1002/cncr.28518

Bianchini, 2014, Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone, Eur J Cancer, 50, 78, 10.1016/j.ejca.2013.08.020

Loriot, 2013, Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol, 24, 1807, 10.1093/annonc/mdt136

Schmid, 2014, Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer, Adv Ther, 31, 234, 10.1007/s12325-014-0092-1

Schrader, 2014, Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone, Eur Urol, 65, 30, 10.1016/j.eururo.2013.06.042

Thomsen, 2014, Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate, Scand J Urol, 48, 268, 10.3109/21681805.2013.860189

Azad, 2015, Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients, Eur Urol, 67, 23, 10.1016/j.eururo.2014.06.045

Brasso K, Thomsen FB, Schrader AJ, et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol, Published online August 6, 2014; http://dx.doi.org/10.1016/j.eururo.2014.07.028.

Suzman, 2014, Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone, Prostate, 74, 1278, 10.1002/pros.22844

Schweizer, 2014, The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer, Eur Urol, 66, 646, 10.1016/j.eururo.2014.01.018

Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815

Thadani-Mulero, 2014, Androgen receptor splice variants determine taxane sensitivity in prostate cancer, Cancer Res, 74, 2270, 10.1158/0008-5472.CAN-13-2876

Ware, 2014, Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer, Endocr Relat Cancer, 21, T87, 10.1530/ERC-13-0470

Arora, 2013, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, Cell, 155, 1309, 10.1016/j.cell.2013.11.012

Joseph, 2013, A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509, Cancer Discov, 3, 1020, 10.1158/2159-8290.CD-13-0226

Korpal, 2013, An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide), Cancer Discov, 3, 1030, 10.1158/2159-8290.CD-13-0142

Beltran, 2011, Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets, Cancer Discov, 1, 487, 10.1158/2159-8290.CD-11-0130

Aggarwal, 2014, Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes, J Natl Compr Canc Netw, 12, 719, 10.6004/jnccn.2014.0073

Taylor, 2010, Integrative genomic profiling of human prostate cancer, Cancer Cell, 18, 11, 10.1016/j.ccr.2010.05.026

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487

Balbas, 2013, Overcoming mutation-based resistance to antiandrogens with rational drug design, Elife, 2, e00499, 10.7554/eLife.00499

Carreira, 2014, Tumor clone dynamics in lethal prostate cancer, Sci Transl Med, 6, 254ra125, 10.1126/scitranslmed.3009448

Li, 2013, Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines, Cancer Res, 73, 483, 10.1158/0008-5472.CAN-12-3630

Al Nakouzi N, Le Moulec S, Albiges L, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol, Published online May 2, 2014; http://dx.doi.org/10.1016/j.eururo.2014.04.015.

Pezaro, 2014, Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents, Eur Urol, 66, 459, 10.1016/j.eururo.2013.11.044

van Soest RJ, de Morree ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol, Published online December 4, 2014; http://dx.doi.org/10.1016/j.eururo.2014.11.033.